T. Rowe Price Group

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the permanent modification of the human genome. This innovative approach enables scientists and clinicians to introduce therapeutic messages into the genome, offering a potential cure for diseases at their source. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics aims to address significant limitations in these areas, enhancing their applicability and effectiveness. Founded by Flagship Pioneering, the company is positioned to transform genetic medicine and improve patient care through its groundbreaking technology.

Developer of life sciences technology intended to develop highly effective and differentiated treatments for cystic fibrosis. The company is developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with cystic fibrosis, enabling patients with best-in-class efficacy and reach and long-term benefit for people with cystic fibrosis.

Cross River Bank, based in Fort Lee, New Jersey, offers a range of personal and corporate banking products and services across the United States. These include checking and savings accounts, as well as direct lending options such as commercial real estate loans for various property types in the New York, New Jersey, and Connecticut metro areas. The bank combines traditional banking practices with innovative technology, partnering with fintech companies to create integrated solutions for marketplace lending and payment processing. Cross River emphasizes regulatory compliance and consumer protection, providing secure banking platforms and services that encompass lending, payments, and risk management. Founded in 2008, Cross River operates as a subsidiary of CRB Group, Inc.

SalioGen Therapeutics advances in curative genetic therapies using its Exact DNA Integration Technology (EDIT) platform, a mammal-derived genome engineering technology. It is focused on providing durable, safe, and affordable non-viral gene therapies to more patients with inherited diseases. Looking ahead, SalioGen will also explore the EDIT platform’s capabilities to streamline cell therapy, cell engineering, and biologics manufacturing to help an even broader population of patients in need.

Generate Biomedicines, Inc. specializes in developing a generative biology platform aimed at inventing novel therapeutic proteins, including antibodies, peptides, enzymes, and other related compounds. Utilizing advanced machine learning techniques, the platform analyzes the genetic code that determines protein function, allowing for the creation of new protein sequences optimized for therapeutic applications. This innovative approach enables the company to generate proteins that interact specifically and effectively with targeted therapeutic needs, facilitating the development of new drugs across various protein modalities. Founded in 2018 and located in Cambridge, Massachusetts, Generate Biomedicines was previously known as Generate Biologics, Inc. until its name change in March 2020.

Chroma Medicine is a genomic medicine company focused on epigenetic editing to transform the treatment of genetically driven diseases. By leveraging epigenetics, which regulates gene expression naturally, Chroma Medicine aims to develop innovative therapies that provide precise control over gene activity. The company utilizes programmable epigenetic editors that combine DNA binding domains with epigenetic effector domains, allowing for targeted manipulation of genes and chromatin structure. This approach promises to create a new class of therapeutics that offers unparalleled control over gene expression, potentially leading to more effective treatments for a range of genetic disorders.

Arbor Biotechnologies operator of a bio-discovery company intended to provide human diagnostic development service. The company's platform employs a diverse set of technologies and techniques including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, enabling drug developers to accelerate the discovery of proteins for improving human health and sustainability.

Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Snyk Ltd. is a developer-focused cybersecurity company that provides a software-as-a-service platform designed to help organizations identify, fix, and monitor vulnerabilities in open-source dependencies and container images. The platform includes tools such as Snyk Code, which offers static application security testing, and container vulnerability management, which addresses vulnerabilities in Docker images. Snyk enables developers to scan their code for security issues directly within their code editors, providing alerts and remediation guidance based on an internal database of known vulnerabilities. The company also offers features for application security management, licensing compliance, and infrastructure as code security. Founded in 2015 and headquartered in London, Snyk has additional offices in Tel Aviv, Boston, and Ontario, and has established a strategic partnership with Rapid7, Inc.

Laronde is focused on developing innovative therapeutics using its proprietary Endless RNA™ (eRNA) platform, which allows for the modulation of human biology through uniquely engineered RNA. This technology enables the expression of diverse proteins within the body while being persistent, non-immunogenic, and suitable for repeat dosing. Additionally, it provides flexibility in formulation and delivery, making it a promising foundation for new medicines. Founded in 2017 by Flagship Labs, Laronde is rapidly scaling its operations to support the simultaneous development of various programs targeting multiple disease areas, aiming to create more predictable and impactful treatments in the healthcare sector.

Ring Therapeutics, Inc. is a biotechnology company that specializes in developing gene therapies through its innovative viral vector platform, Anellovector. This platform leverages the human commensal virome to create redosable and targetable DNA therapies, addressing key limitations of existing gene and DNA treatments, such as restricted access to diverse tissues and challenges with tolerability and genomic integration. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics aims to expand the scope of gene therapy beyond traditional gene replacement, enabling a broader range of applications across various medical fields, including genetic disorders, ophthalmology, oncology, and metabolic diseases. By focusing on cellular and tissue specificity, the company aspires to unlock new therapeutic possibilities for previously inaccessible conditions.

Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.

LUMICKS B.V. is a company that specializes in developing advanced equipment for dynamic single-molecule and cell avidity analysis, facilitating research in biology and cancer at the molecular and cellular levels. Founded in 2014 and headquartered in Amsterdam, with an additional office in Cambridge, Massachusetts, LUMICKS offers innovative technologies such as correlative optical tweezers-fluorescence microscopy systems and the C-Trap, which integrates optical tweezers with advanced imaging techniques. The company’s Acoustic Force Spectroscopy (AFS) enables the study of mechanical properties in biological systems, while its u-Flux microfluidics system allows for single-molecule experiments in controlled laminar flow environments. By enabling live measurements and imaging of molecular interactions, LUMICKS provides valuable insights into the fundamental causes of diseases, including cancer, and supports drug optimization efforts.

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the drug development process through an asset-centric research and development model. The company advances a diverse portfolio of validated programs, each managed by a dedicated subsidiary and backed by a centralized infrastructure and experienced management team. Among its pipeline assets are SerpinPC, targeting Hemophilia A and B, LB101 for solid tumors, ORX750 for narcolepsy type 1 and other sleep disorders, and MGX292 for pulmonary arterial hypertension. Additionally, Centessa is developing an undisclosed asset for solid tumors.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, that specializes in developing vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins in a single vaccine, aiming to enhance the immune response against various infectious diseases. Affinivax focuses on a range of pathogens, including Streptococcus pneumoniae, which poses significant health risks to both children and adults. The company seeks to create vaccines that provide broader disease coverage and address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from insights provided by leading experts in infectious diseases and vaccines, and it has secured support from the Bill & Melinda Gates Foundation, along with exclusive licensing rights from Boston Children’s Hospital for its MAPS technology.

FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.

DataRobot, Inc. develops an automated machine learning platform designed to help enterprises build predictive models efficiently. The company's offerings include DataRobot Cloud, a predictive analytics platform available on-site or via the cloud, and DataRobot MLOps, which focuses on the deployment, monitoring, and management of machine learning models within organizations. Additionally, DataRobot Enterprise provides features such as flexible deployment, governance, and support, along with packages aimed at accelerating artificial intelligence projects and education services. The platform is suitable for a diverse range of professionals, including business analysts, data scientists, and IT specialists across various industries like banking, healthcare, and marketing. Founded in 2012 and headquartered in Boston, Massachusetts, DataRobot also maintains operations in several international locations, including London, Paris, Kyiv, Tokyo, and Singapore. The company has established strategic partnerships to enhance its offerings in the competitive AI landscape.

Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.

Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.

C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.

Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses. Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.

HaulHub is a technology company that offers a specialized platform designed for heavy construction firms, focusing on transportation and digital ticketing solutions for producers and contractors. Founded in 2015 by Joe Spinelli, HaulHub collaborates with material producers, general contractors, fleet owners, and carriers across the United States. The platform enhances industrial construction operations by automating scheduling, providing real-time GPS tracking, facilitating electronic payment processing, and delivering data analytics. This comprehensive approach allows contractors and fleet owners to streamline material movement, eliminate inefficient paper-based processes, and improve logistics efficiency. HaulHub's commitment to innovation and workplace excellence was recognized when it was named one of Built In Boston's 'Best Places to Work: Small Companies' in 2020.

HaulHub is a technology company that offers a specialized platform designed for heavy construction firms, focusing on transportation and digital ticketing solutions for producers and contractors. Founded in 2015 by Joe Spinelli, HaulHub collaborates with material producers, general contractors, fleet owners, and carriers across the United States. The platform enhances industrial construction operations by automating scheduling, providing real-time GPS tracking, facilitating electronic payment processing, and delivering data analytics. This comprehensive approach allows contractors and fleet owners to streamline material movement, eliminate inefficient paper-based processes, and improve logistics efficiency. HaulHub's commitment to innovation and workplace excellence was recognized when it was named one of Built In Boston's 'Best Places to Work: Small Companies' in 2020.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.

Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Toast, Inc. is a Boston-based company that specializes in developing a comprehensive point-of-sale and restaurant management platform tailored for the foodservice and hospitality industries. Founded in 2011, Toast provides cloud-based solutions that include online ordering, delivery tracking, tableside ordering, and labor management, all designed to streamline restaurant operations. The platform serves a diverse range of establishments, including restaurants, cafés, bars, and nightclubs, enabling them to enhance customer experiences and optimize business performance. By offering software subscription services, processing transaction fees, and providing financing through its Toast Capital division, Toast supports over 120,000 restaurant locations across the United States. The company stands out by processing a significant volume of financial transactions on its platform, reinforcing its commitment to delivering a robust and effective technology solution for restaurateurs.

Toast, Inc. is a Boston-based company that specializes in developing a comprehensive point-of-sale and restaurant management platform tailored for the foodservice and hospitality industries. Founded in 2011, Toast provides cloud-based solutions that include online ordering, delivery tracking, tableside ordering, and labor management, all designed to streamline restaurant operations. The platform serves a diverse range of establishments, including restaurants, cafés, bars, and nightclubs, enabling them to enhance customer experiences and optimize business performance. By offering software subscription services, processing transaction fees, and providing financing through its Toast Capital division, Toast supports over 120,000 restaurant locations across the United States. The company stands out by processing a significant volume of financial transactions on its platform, reinforcing its commitment to delivering a robust and effective technology solution for restaurateurs.

Quanterix Corporation is a life sciences company focused on developing an advanced platform for single-molecule analysis, known for its ultra-sensitive digital immunoassay technology. This innovative approach enables precise detection and quantification of individual proteins and small molecules in complex biological samples, which is critical for clinical diagnostics, drug development, and life science research. Quanterix's flagship technology, Simoa, allows for the reliable measurement of protein biomarkers in extremely low concentrations, surpassing conventional immunoassay methods. The company offers a range of products, including assay kits, specialized assays for neurodegenerative diseases, and advanced instrumentation designed to enhance early disease detection and improve patient outcomes. Founded in 2007, Quanterix is supported by prominent life science investors, positioning it to address significant unmet medical needs and contribute to advancements in healthcare.

Editas Medicine is a clinical-stage company focused on developing innovative genome editing therapeutics to address serious diseases at the genetic level. Established in 2013 and headquartered in Cambridge, Massachusetts, with an additional site in Boulder, Colorado, the company leverages its proprietary CRISPR/Cas9 technology to create precise and corrective molecular modifications. This approach utilizes a protein-RNA complex, which includes the Cas9 enzyme and a guide RNA, to target and repair specific DNA sequences. Editas Medicine aims to translate its advances in genome editing into transformative human therapies, supported by a robust portfolio of patents and intellectual property that underpins its foundational technologies.

Sweetgreen, Inc. is an American fast-casual restaurant chain founded in 2007 and based in Culver City, California. It operates restaurants in several states, including Virginia, Pennsylvania, New York, Maryland, Massachusetts, and the District of Columbia. The company focuses on serving simple, seasonal, and healthy salads and grain bowls made from scratch with fresh, whole produce delivered daily. Sweetgreen emphasizes plant-forward, earth-friendly meals, prioritizing organic, regenerative, and local sourcing of ingredients. In addition to its restaurant operations, Sweetgreen sells merchandise such as gift cards, clothing, and accessories online. The company has formed a strategic partnership with FoodCorps to further its mission of promoting healthy eating.

BeiGene, Ltd. is a biotechnology company engaged in the development and commercialization of targeted and immuno-oncology therapies for cancer. Founded in 2010 and based in Beijing, the company operates globally, focusing on addressing significant unmet medical needs across various cancer types. Its commercial portfolio includes treatments such as BRUKINSA for mantle cell lymphoma and Tislelizumab for Hodgkin's lymphoma, alongside other therapies for conditions like breast cancer and multiple myeloma. BeiGene's pipeline features several clinical-stage drug candidates, including Zanubrutinib, an inhibitor targeting Bruton's tyrosine kinase, and Pamiparib, a PARP inhibitor. The company is dedicated to making innovative cancer treatments more affordable and accessible, and it collaborates with various pharmaceutical firms to enhance its research and development efforts.

Luminex Trading & Analytics specializes in providing an equity trading platform designed to enhance the efficiency of institutional investors in sourcing block liquidity. The platform facilitates access to clean and natural block liquidity while significantly reducing trading costs. By engaging exclusively with venue-approved participants, Luminex ensures low-cost trading with minimal information leakage, thereby allowing traders to execute large block trades with reduced market impact. This focus on transparency and cost-effectiveness positions Luminex as a valuable resource for the institutional money management community.

Lookout is a cybersecurity company that predicts and stops mobile attacks before harm is done to an individual or an enterprise. Lookout’s cloud-based technology is fueled by a global sensor network of more than 60 million users and tens of thousands of apps that are added daily. With this dataset of virtually all the mobile code in the world and the predictive machine intelligence to analyze and make sense of the data, Lookout can identify connections that would otherwise go unseen and stop cybercriminals from attacking mobile devices. Headquartered in San Francisco, Lookout has offices in Boston, London, Singapore, Tokyo, Toronto and Washington, D.C.

Wayfair Inc. is a prominent e-commerce retailer specializing in home goods, operating primarily in the United States, Canada, the United Kingdom, Germany, and Ireland. Founded in 2002 and headquartered in Boston, Massachusetts, the company provides a vast selection of over 30 million products through its various brands, including Wayfair, Joss & Main, AllModern, Birch Lane, and Perigold. The product categories encompass furniture, décor, kitchen and dining items, home improvement goods, and seasonal decorations. Wayfair has recently begun expanding into physical retail, establishing a number of brick-and-mortar locations. With a workforce of over 2,300 employees, Wayfair has solidified its position as the largest pure-play online retailer of home goods in the U.S. and continues to innovate in the e-commerce landscape.

TESARO, Inc. is an oncology-focused biopharmaceutical company established in 2010 and based in Waltham, Massachusetts. The company specializes in the identification, acquisition, development, and commercialization of cancer therapeutics and supportive care products. Its notable offerings include ZEJULA, an oral poly polymerase inhibitor used for the maintenance treatment of recurrent ovarian cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. TESARO is also advancing a range of immunotherapy candidates, such as TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company has formed various collaboration and licensing agreements with industry partners, including AnaptysBio, Janssen Biotech, and Genentech. In January 2019, TESARO became a subsidiary of GlaxoSmithKline plc, further enhancing its capabilities in cancer treatment innovation.

As of January 2001, AllAdvantage Inc. went out of business. AllAdvantage.com, Inc. operates as an Internet advertising company. It pays its users/members a portion of the advertising revenue generated by their online viewing habits. The company also allows members to receive membership benefits that include sponsor discounts and rebates for surfing the Web. In addition, it provides incentives for advertisers to build one-on-one relationships with its members. The company was founded in 1999 and is based in Hayward, California with additional offices in Atlanta, Boston, Chicago, Dallas, Detroit, Hayward, London, Los Angeles, New York, Paris, Seattle, Sydney, and Washington DC.